TABLE 2.

Evaluation of seroconversion panels with frequently obtained samples

Panel and panel member	No. of days since first bleed	S/CO
		HIV-1/2 RNA qualitative assay	Monoclonal antigen detection test	HIV-1/2 antibody detection test
PRB936
1a	0		0.3	0.1
2	5	2.9b	0.3	0.1
3	7	5.6	0.4	0.1
4	12	5.8	13	0.1
5	14	5.8	>31.7	0.1
6	19	6.2	>31.7	1.5
PRB937
1	0	0.2	0.3	0.1
2	7	4.1	0.3	0.1
3	9	5.7	0.3	0.1
4	14	5.6	2.1	0.1
5	16	6.2	3.2	0.1
6	21	5.8	13.6	1
PRB943
1	0	0.1	0.4	0.1
2	5	4.7	0.4	0.1
3	7	4.7	0.7	0.1
4	12	6	10.6	0.2
5	14	6.5	25.6	2.5
PRB944
1	0	4.5	0.5	0.1
2	2	4.3	1	0.1
3	7	5.4	6.6	0.1
4	9	4	7	0.6
5	14	4.9	5.8	11.7
PRB945
1	0	0.2	0.4	0.1
2	3	1.7	0.4	0.1
3	7	4.7	0.7	0.1
4	13	4.9	4	2.9
PRB952
1	0	0.1	0.4	0.2
2	7	2	0.5	0.2
3	10	3.7	2.3	0.2
4	14	3.3	1.2	1
6243
4	12	0.6	0.49	0.43
5	18	2.2	0.49	0.43
6	20	4.6	0.49	0.44
7	25	5.5	0.93	0.47
8	27	6.1	1.04	0.53
9	32	6.2	0.88	4.39
6244
10	22	0.5	0.44	0.37
11	25	3.8	0.46	0.38
12	26	4.5	0.51	0.37
13	28	5.2	1.33	0.41
14	33	5.6	18.33	2.17
6245
4	55	0.2	0.47	0.36
5	60	3.1	0.53	0.38
6	66	5.7	1.44	0.47
7	69	5.6	4.91	0.41
8	73	6.1	11.1	1.32

^aPanel member 1 was not supplied by the vendor. 

^bBoldface numbers represent the first positive result by each test.